Crossmark

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s13643-017-0588-2

Published Online: 2017-10-10

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wilson, Florence R. https://orcid.org/0000-0001-6221-3106
Coombes, Megan E.

Wylie, Quinlan

Yurchenko, Mariya

Brezden-Masley, Christine

Hutton, Brian

Skidmore, Becky

Cameron, Chris
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche (CH)